1
|
Devillier P, Wahn U, Richter H, Hadler M, Karagiannis E, Girard L. P106 Treatment with grass pollen slit tablets is associated with long-term relief of allergic conjunctivitis. Ann Allergy Asthma Immunol 2017. [DOI: 10.1016/j.anai.2017.08.130] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
2
|
Wang K, Sanchez-Martin M, Wang X, Knapp KM, Koche R, Vu L, Nahas MK, He J, Hadler M, Stein EM, Tallman MS, Donahue AL, Frampton GM, Lipson D, Roels S, Stephens PJ, Sanford EM, Brennan T, Otto GA, Yelensky R, Miller VA, Kharas MG, Levine RL, Ferrando A, Armstrong SA, Krivtsov AV. Patient-derived xenotransplants can recapitulate the genetic driver landscape of acute leukemias. Leukemia 2016; 31:151-158. [PMID: 27363283 PMCID: PMC5203983 DOI: 10.1038/leu.2016.166] [Citation(s) in RCA: 48] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2016] [Revised: 05/25/2016] [Accepted: 05/31/2016] [Indexed: 12/20/2022]
Abstract
Genomic studies have identified recurrent somatic mutations in acute leukemias. However, current murine models do not sufficiently encompass the genomic complexity of human leukemias. To develop pre-clinical models, we transplanted 160 samples from patients with acute leukemia (AML, MLL, B-ALL and T-ALL) into immunodeficient mice. Of these, 119 engrafted with expected immunophenotype. Targeted sequencing of 374 genes and 265 frequently rearranged RNAs detected recurrent and novel genetic lesions in 48 paired primary tumor (PT) and patient-derived xenotransplant (PDX) samples. Overall, the frequencies of 274 somatic variant alleles correlated between PT and PDX samples, although the data were highly variable for variant alleles present at 0-10%. 17% of variant alleles were detected in either PT or PDX samples only. Based on variant allele frequency changes, 24 PT-PDX pairs were classified as concordant while the other 24 pairs showed various degree of clonal discordance. There was no correlation of clonal concordance with clinical parameters of diseases. Significantly more bone marrow samples than peripheral blood samples engrafted discordantly. These data demonstrate the utility of developing PDX banks for modeling human leukemia, and emphasize the importance of genomic profiling of PDX and patient samples to ensure concordance before performing mechanistic or therapeutic studies.
Collapse
Affiliation(s)
- K Wang
- Foundation Medicine, Cambridge, MA, USA
| | - M Sanchez-Martin
- Institute for Cancer Genetics Columbia University, New York, NY, USA
| | - X Wang
- Center for Epigenetic Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - K M Knapp
- Center for Epigenetic Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - R Koche
- Center for Epigenetic Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - L Vu
- Center for Epigenetic Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - M K Nahas
- Foundation Medicine, Cambridge, MA, USA
| | - J He
- Foundation Medicine, Cambridge, MA, USA
| | - M Hadler
- Foundation Medicine, Cambridge, MA, USA
| | - E M Stein
- Center for Epigenetic Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - M S Tallman
- Center for Epigenetic Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | | | | | - D Lipson
- Foundation Medicine, Cambridge, MA, USA
| | - S Roels
- Foundation Medicine, Cambridge, MA, USA
| | | | | | - T Brennan
- Foundation Medicine, Cambridge, MA, USA
| | - G A Otto
- Foundation Medicine, Cambridge, MA, USA
| | | | | | - M G Kharas
- Center for Epigenetic Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - R L Levine
- Center for Epigenetic Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - A Ferrando
- Institute for Cancer Genetics Columbia University, New York, NY, USA
| | - S A Armstrong
- Center for Epigenetic Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - A V Krivtsov
- Center for Epigenetic Research, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| |
Collapse
|
3
|
Yi JS, Federation AJ, Qi J, Dhe-Paganon S, Hadler M, Xu X, St. Pierre R, Varca AC, Wu L, Marineau JJ, Smith WB, Souza A, Chory EJ, Armstrong SA, Bradner JE. Structure-guided DOT1L probe optimization by label-free ligand displacement. ACS Chem Biol 2015; 10:667-74. [PMID: 25397901 PMCID: PMC4504433 DOI: 10.1021/cb500796d] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
![]()
The
DOT1L lysine methyltransferase has emerged as a validated therapeutic
target in MLL-rearranged (MLLr) acute leukemias.
Although S-adenosylmethionine competitive inhibitors have demonstrated
pharmacological proof-of-principle in MLLr-leukemia,
these compounds require further optimization to improve cellular potency
and pharmacokinetic stability. Limiting DOT1L inhibitor discovery
and ligand optimization have been complex biochemical methods often
using radionucleotides and cellular methods requiring prolonged culture.
We therefore developed a new suite of assay technologies that allows
comparative assessment of chemical tools for DOT1L in a miniaturized
format. Coupling these assays with structural information, we developed
new insights into DOT1L ligand binding and identified several functionalized
probes with increased cellular potency (IC50 values ∼10
nM) and excellent selectivity for DOT1L. Together these assay technologies
define a platform capability for discovery and optimization of small-molecule
DOT1L inhibitors.
Collapse
Affiliation(s)
- Joanna S. Yi
- Department
of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- Department
of Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- Department
of Pediatrics, Harvard Medical School, Boston, Massachusetts, United States
| | - Alexander J. Federation
- Department
of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
| | - Jun Qi
- Department
of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
| | - Sirano Dhe-Paganon
- Department
of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
| | - Michael Hadler
- Human
Oncology and Pathogenesis Program, Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, United States
| | - Xiang Xu
- Department
of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, Massachusetts, United States
| | - Roodolph St. Pierre
- Department
of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
| | - Anthony C. Varca
- Department
of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
| | - Lei Wu
- Shanghai ChemPartner Co. Ltd., 998 Hailei Road, Zhangjiang Hi-Tech Park, Pudong
New Area, Shanghai, 201203, China
| | - Jason J. Marineau
- Department
of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
| | - William B. Smith
- Department
of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
| | - Amanda Souza
- Department
of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
| | - Emma J. Chory
- Department
of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
| | - Scott A. Armstrong
- Human
Oncology and Pathogenesis Program, Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, United States
| | - James E. Bradner
- Department
of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, United States
- Department
of Medicine, Harvard Medical School, Boston, Massachusetts, United States
| |
Collapse
|
4
|
Bredel M, Ferrarese R, Harsh GR, Yadav AK, Bug E, Maticzka D, Reichardt W, Masilamani AP, Dai F, Kim H, Hadler M, Scholtens DM, Yu ILY, Beck J, Srinivasasainagendra V, Costa F, Baxan N, Pfeifer D, Elverfeldt DV, Backofen R, Weyerbrock A, Duarte CW, He X, Prinz M, Chandler JP, Vogel H, Chakravarti A, Rich JN, Carro MS. ABERRANT SPLICING OF A BRAIN-ENRICHED ALTERNATIVE EXON ELIMINATES TUMOR SUPPRESSOR FUNCTION AND PROMOTES ONCOGENE FUNCTION DURING BRAIN TUMORIGENESIS. Neuro Oncol 2014. [DOI: 10.1093/neuonc/nou206.71] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
5
|
Ferrarese R, Harsh GR, Yadav AK, Bug E, Maticzka D, Reichardt W, Dombrowski SM, Miller TE, Masilamani AP, Dai F, Kim H, Hadler M, Scholtens DM, Yu ILY, Beck J, Srinivasasainagendra V, Costa F, Baxan N, Pfeifer D, von Elverfeldt D, Backofen R, Weyerbrock A, Duarte CW, He X, Prinz M, Chandler JP, Vogel H, Chakravarti A, Rich JN, Carro MS, Bredel M. Lineage-specific splicing of a brain-enriched alternative exon promotes glioblastoma progression. J Clin Invest 2014; 124:2861-76. [PMID: 24865424 DOI: 10.1172/jci68836] [Citation(s) in RCA: 65] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/03/2013] [Accepted: 04/03/2014] [Indexed: 01/08/2023] Open
Abstract
Tissue-specific alternative splicing is critical for the emergence of tissue identity during development, yet the role of this process in malignant transformation is undefined. Tissue-specific splicing involves evolutionarily conserved, alternative exons that represent only a minority of the total alternative exons identified. Many of these conserved exons have functional features that influence signaling pathways to profound biological effect. Here, we determined that lineage-specific splicing of a brain-enriched cassette exon in the membrane-binding tumor suppressor annexin A7 (ANXA7) diminishes endosomal targeting of the EGFR oncoprotein, consequently enhancing EGFR signaling during brain tumor progression. ANXA7 exon splicing was mediated by the ribonucleoprotein PTBP1, which is normally repressed during neuronal development. PTBP1 was highly expressed in glioblastomas due to loss of a brain-enriched microRNA (miR-124) and to PTBP1 amplification. The alternative ANXA7 splicing trait was present in precursor cells, suggesting that glioblastoma cells inherit the trait from a potential tumor-initiating ancestor and that these cells exploit this trait through accumulation of mutations that enhance EGFR signaling. Our data illustrate that lineage-specific splicing of a tissue-regulated alternative exon in a constituent of an oncogenic pathway eliminates tumor suppressor functions and promotes glioblastoma progression. This paradigm may offer a general model as to how tissue-specific regulatory mechanisms can reprogram normal developmental processes into oncogenic ones.
Collapse
|
6
|
Samon JB, Castillo-Martin M, Hadler M, Ambesi-Impiobato A, Paietta E, Racevskis J, Wiernik PH, Rowe JM, Jakubczak J, Randolph S, Cordon-Cardo C, Ferrando AA. Preclinical analysis of the γ-secretase inhibitor PF-03084014 in combination with glucocorticoids in T-cell acute lymphoblastic leukemia. Mol Cancer Ther 2012; 11:1565-75. [PMID: 22504949 DOI: 10.1158/1535-7163.mct-11-0938] [Citation(s) in RCA: 88] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
T-cell acute lymphoblastic leukemias (T-ALL) and lymphomas are aggressive hematologic cancers frequently associated with activating mutations in NOTCH1. Early studies identified NOTCH1 as an attractive therapeutic target for the treatment of T-ALL through the use of γ-secretase inhibitors (GSI). Here, we characterized the interaction between PF-03084014, a clinically relevant GSI, and dexamethasone in preclinical models of glucocorticoid-resistant T-ALL. Combination treatment of the GSI PF-03084014 with glucocorticoids induced a synergistic antileukemic effect in human T-ALL cell lines and primary human T-ALL patient samples. Mechanistically PF-03084014 plus glucocorticoid treatment induced increased transcriptional upregulation of the glucocorticoid receptor and glucocorticoid target genes. Treatment with PF-03084014 and glucocorticoids in combination was highly efficacious in vivo, with enhanced reduction of tumor burden in a xenograft model of T-ALL. Finally, glucocorticoid treatment effectively reversed PF-03084014-induced gastrointestinal toxicity via inhibition of goblet cell metaplasia. These results warrant the analysis of PF-03084014 and glucocorticoids in combination for the treatment of glucocorticoid-resistant T-ALL.
Collapse
Affiliation(s)
- Jeremy B Samon
- Department of Pathology, Institute for Cancer Genetics, Columbia University, New York, NY 10032, USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Ntziachristos P, Tsirigos A, Van Vlierberghe P, Nedjic J, Trimarchi T, Flaherty MS, Ferres-Marco D, da Ros V, Tang Z, Siegle J, Asp P, Hadler M, Rigo I, De Keersmaecker K, Patel J, Huynh T, Utro F, Poglio S, Samon JB, Paietta E, Racevskis J, Rowe JM, Rabadan R, Levine RL, Brown S, Pflumio F, Dominguez M, Ferrando A, Aifantis I. Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nat Med 2012; 18:298-301. [PMID: 22237151 PMCID: PMC3274628 DOI: 10.1038/nm.2651] [Citation(s) in RCA: 387] [Impact Index Per Article: 32.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2011] [Accepted: 12/21/2011] [Indexed: 12/13/2022]
Abstract
T-cell acute lymphoblastic leukemia (T-ALL) is an immature hematopoietic malignancy driven mainly by oncogenic activation of NOTCH1 signaling1. In this study we report the presence of loss-of-function mutations and deletions of EZH2 and SUZ12 genes, encoding critical components of the Polycomb Repressive Complex 2 (PRC2) complex2,3, in 25% of T-ALLs. To further study the role of the PRC2 complex in T-ALL, we used NOTCH1-induced animal models of the disease, as well as human T-ALL samples, and combined locus-specific and global analysis of NOTCH1-driven epigenetic changes. These studies demonstrated that activation of NOTCH1 specifically induces loss of the repressive mark lysine-27 tri-methylation of histone 3 (H3K27me3)4 by antagonizing the activity of the Polycomb Repressive Complex 2 (PRC2) complex. These studies demonstrate a tumor suppressor role for the PRC2 complex in human leukemia and suggest a hitherto unrecognized dynamic interplay between oncogenic NOTCH1 and PRC2 function for the regulation of gene expression and cell transformation.
Collapse
Affiliation(s)
- Panagiotis Ntziachristos
- Howard Hughes Medical Institute and Department of Pathology, New York University School of Medicine, New York, New York, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Van Vlierberghe P, Ambesi-Impiombato A, Perez-Garcia A, Haydu JE, Rigo I, Hadler M, Tosello V, Della Gatta G, Paietta E, Racevskis J, Wiernik PH, Luger SM, Rowe JM, Rue M, Ferrando AA. ETV6 mutations in early immature human T cell leukemias. J Exp Med 2011; 208:2571-9. [PMID: 22162831 PMCID: PMC3244026 DOI: 10.1084/jem.20112239] [Citation(s) in RCA: 151] [Impact Index Per Article: 11.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2011] [Accepted: 11/30/2011] [Indexed: 11/15/2022] Open
Abstract
Early immature T cell acute lymphoblastic leukemias (T-ALLs) account for ~5-10% of pediatric T-ALLs and are associated with poor prognosis. However, the genetic defects that drive the biology of these tumors remain largely unknown. In this study, analysis of microarray gene expression signatures in adult T-ALL demonstrated a high prevalence of early immature leukemias and revealed a close relationship between these tumors and myeloid leukemias. Many adult immature T-ALLs harbored mutations in myeloid-specific oncogenes and tumor suppressors including IDH1, IDH2, DNMT3A, FLT3, and NRAS. Moreover, we identified ETV6 mutations as a novel genetic lesion uniquely present in immature adult T-ALL. Our results demonstrate that early immature adult T-ALL represents a heterogeneous category of leukemias characterized by the presence of overlapping myeloid and T-ALL characteristics, and highlight the potential role of ETV6 mutations in these tumors.
Collapse
Affiliation(s)
- Pieter Van Vlierberghe
- Institute for Cancer Genetics, Department of Pediatrics, and Department of Pathology, Columbia University Medical Center, New York, NY 10032
| | - Alberto Ambesi-Impiombato
- Institute for Cancer Genetics, Department of Pediatrics, and Department of Pathology, Columbia University Medical Center, New York, NY 10032
| | - Arianne Perez-Garcia
- Institute for Cancer Genetics, Department of Pediatrics, and Department of Pathology, Columbia University Medical Center, New York, NY 10032
| | - J. Erika Haydu
- Institute for Cancer Genetics, Department of Pediatrics, and Department of Pathology, Columbia University Medical Center, New York, NY 10032
| | - Isaura Rigo
- Institute for Cancer Genetics, Department of Pediatrics, and Department of Pathology, Columbia University Medical Center, New York, NY 10032
| | - Michael Hadler
- Institute for Cancer Genetics, Department of Pediatrics, and Department of Pathology, Columbia University Medical Center, New York, NY 10032
| | - Valeria Tosello
- Institute for Cancer Genetics, Department of Pediatrics, and Department of Pathology, Columbia University Medical Center, New York, NY 10032
| | - Giusy Della Gatta
- Institute for Cancer Genetics, Department of Pediatrics, and Department of Pathology, Columbia University Medical Center, New York, NY 10032
| | | | | | | | - Selina M. Luger
- Hematologic Malignancies and Stem Cell Transplant Program, Hematology-Oncology Division, University of Pennsylvania Medical Center, Philadelphia, PA 19104
| | | | - Montserrat Rue
- Department of Basic Medical Sciences, University of Lleida, Lleida 25003, Spain
| | - Adolfo A. Ferrando
- Institute for Cancer Genetics, Department of Pediatrics, and Department of Pathology, Columbia University Medical Center, New York, NY 10032
| |
Collapse
|
9
|
De Keersmaecker K, Real PJ, Gatta GD, Palomero T, Sulis ML, Tosello V, Van Vlierberghe P, Barnes K, Castillo M, Sole X, Hadler M, Lenz J, Aplan PD, Kelliher M, Kee BL, Pandolfi PP, Kappes D, Gounari F, Petrie H, Van der Meulen J, Speleman F, Paietta E, Racevskis J, Wiernik PH, Rowe JM, Soulier J, Avran D, Cavé H, Dastugue N, Raimondi S, Meijerink JPP, Cordon-Cardo C, Califano A, Ferrando AA. The TLX1 oncogene drives aneuploidy in T cell transformation. Nat Med 2010; 16:1321-7. [PMID: 20972433 PMCID: PMC2974790 DOI: 10.1038/nm.2246] [Citation(s) in RCA: 121] [Impact Index Per Article: 8.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2010] [Accepted: 09/21/2010] [Indexed: 11/09/2022]
Abstract
The TLX1 transcription factor oncogene plays an important role in the pathogenesis of T-cell acute lymphoblastic leukemia (T-ALL). However, the specific mechanisms of T-cell transformation downstream of TLX1 remain to be elucidated. Here we show that forced expression of TLX1 in transgenic mice induces T-ALL tumors with frequent deletions and mutations in Bcl11b, and identify the presence of recurrent mutations and deletions in BCL11B in 16% of human T-ALLs. Most notably, mouse TLX1 tumors were typically aneuploid and showed a marked defect in the activation of the mitotic checkpoint. Mechanistically, TLX1 directly downregulates the expression of CHEK1 and additional mitotic control genes and induces loss of the mitotic checkpoint in non transformed preleukemic thymocytes. These results identify a novel mechanism contributing to chromosomal missegregation and aneuploidy active at the earliest stages of tumor development in the pathogenesis of cancer.
Collapse
|
10
|
Garrett L, Hadler M, Hardy S, Hou T, Middleton L. Knowledge and attitudes on screening for cervical cancer. N Z Med J 1986; 99:597. [PMID: 3462553] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/05/2023]
|